Finance

Roʻyxatlar
TEVA:NYSE
Teva Pharmaceutical Industries Limited
41,11 US$
+0,91%
(+0,37) 1K
41,40 US$
+0,71% (+0,29)
Birjadan oldin
Savdolar yopilgan: 15-okt, 16:00:05 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
TEVA tikeri uchun statistika yaratilmoqda...
Ochish
41,30 US$
Yuqori
41,85 US$
Past
41,03 US$
Bozor kapitali
47,13 mlrd
Oʻrtacha hajm
5,87 mln
Hajmi
11,29 ming
52 haftalik eng yuqori
42,02 US$
52 haftalik eng past
18,82 US$
Beta
1,07
Muomaladagi aksiyalar
1,17 mlrd
Xodimlar soni
32 ming
Ochish
41,30 US$
Yuqori
41,85 US$
Past
41,03 US$
Bozor kapitali
47,13 mlrd
Oʻrtacha hajm
5,87 mln
Hajmi
11,29 ming
52 haftalik eng yuqori
42,02 US$
52 haftalik eng past
18,82 US$
Beta
1,07
Muomaladagi aksiyalar
1,17 mlrd
Xodimlar soni
32 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients and, to a lesser extent, contract manufacturing services and an out-licensing platform. Teva's primary branded products include Austedo which is used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia; and Ajovy, used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange. Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of the Pharmaceutical Research and Manufacturers of America. Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 26th largest pharmaceutical company in the world. Teva has a history of legal trouble in relation to collusion and price-fixing to inflate prices for drugs. Wikipedia
Teva Pharmaceutical Industries Limited haqida
CEORichard Francis
Xodimlar soni32 ming
Asos solingan13-fev, 1944
Bosh ofislar-
Sektor-
Veb-saytteva.co.il
Analitik reytinglar
Oxirgi 3 oyda TEVA aksiyalari boʻyicha reyting bergan 9 tahlilchi xulosasiga koʻra
Sotib olish tavsiya etiladi
Sotib olish
9
Ushlab qolish
0
Sotish
0
12 oylik prognoz
Oxirgi 3 oyda TEVA uchun 12 oylik narx maqsadlarini taklif qilgan 9 Wall Street tahlilchisi xulosasiga koʻra
Eng yuqori
Joriy 41,11 US$
50,00 US$ (+21,62%)
O‘rtacha
44,00 US$ (+7,03%)
Eng past
40,00 US$ (-2,70%)
Analitik
Tavsiya
Amal
Kutilayotgan narx
Prognoz
Sana
Daniel Clark
Leerink Partners
Buy
Initiated
45,00 US$
+9,5%
09/09/2026
Ashwani Verma
UBS
Buy
Maintained
48,00 US$
+16,8%
09/04/2026
Dennis Ding
Jefferies
Buy
Maintained
40,00 US$
-2,7%
09/03/2026
Louise Chen
Scotiabank
Buy
Maintained
40,00 US$
-2,7%
09/03/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
50,00 US$
+21,6%
09/02/2026
Jason Gerberry
Bank of America Securities
Buy
Reiterated
43,00 US$
+4,6%
09/02/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
09/02/2026
David Amsellem
Piper Sandler
Buy
Reiterated
44,00 US$
+7%
08/27/2026
Glen Santangelo
Barclays
Buy
Maintained
42,00 US$
+2,2%
08/12/2026
Chris Schott
J.P. Morgan
Buy
Maintained
-
-
06/15/2026
Matthew Dellatorre
Goldman Sachs
Buy
Maintained
50,00 US$
+21,6%
04/30/2026
Les Sulewski
Truist Financial
Buy
Reiterated
45,00 US$
+9,5%
04/30/2026
Oxirgi hisobot
29-iyl, 2026
Moliya davri
Ch.2 2026
0,02 US$ / 0,11 US$
-81,46%manfiy
Taxminiy daromad (USD)
4,14 mlrd / 4,03 mlrd
+2,79%musbat
Q2 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
sen, 2025
dek, 2025
mar, 2026
iyn, 2026
Daromad
4,48 mlrd
4,71 mlrd
3,98 mlrd
4,14 mlrd
Sotilgan mahsulotning tannarxi
2,18 mlrd
2,06 mlrd
2,01 mlrd
1,99 mlrd
Daromad narxi
2,18 mlrd
2,06 mlrd
2,01 mlrd
1,99 mlrd
Tadqiqot va ishlanmalarga xarajatlar
256,00 mln
267,00 mln
222,00 mln
970,00 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
973,00 mln
1,12 mlrd
1,00 mlrd
1,03 mlrd
Operatsion xarajatlar
1,24 mlrd
1,37 mlrd
1,21 mlrd
1,99 mlrd
Jami operatsion xarajatlar
3,41 mlrd
3,43 mlrd
3,22 mlrd
3,98 mlrd
Operatsion daromad
1,07 mlrd
1,28 mlrd
763,00 mln
167,00 mln
Boshqa nooperatsion daromad
-27,00 mln
-
-13,00 mln
-69,00 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
648,00 mln
90,00 mln
436,00 mln
-455,00 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
832,00 mln
1,08 mlrd
547,00 mln
-57,00 mln
Daromad soligʻi boʻyicha xarajat
214,00 mln
-390,00 mln
67,00 mln
121,00 mln
Amaldagi soliq stavkasi
33,02%
-433,33%
15,37%
-26,59%
Boshqa operatsion xarajatlar
9,00 mln
-17,00 mln
-14,00 mln
-18,00 mln
Sof foyda
433,00 mln
480,00 mln
369,00 mln
-576,00 mln
Sof foyda marjasi
9,67%
10,19%
9,27%
-13,91%
Har bir aksiya foydasi
0,78
0,96
0,53
0,02
Foizlar va investitsiyalardan olingan daromadlar
-
92,00 mln
-
-
Foizlarni toʻlash xarajatlari
-205,00 mln
-280,00 mln
-191,00 mln
-186,00 mln
Foizlarni toʻlash boʻyicha sof xarajatlar
-205,00 mln
-188,00 mln
-191,00 mln
-186,00 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
1,32 mlrd
1,54 mlrd
1,00 mlrd
408,00 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-8,00 mln
-12,00 mln
Insayder tranzaksiyalari
Insayder tranzaksiyalari maʼlumotlari tashqi manbalardan olingan. Batafsil
Insayder
Joylashuvi
Turi
Sana
Aksiyalar
Miqdor
1-sahifa
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari